Lv2
190 积分 2024-05-09 加入
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
3天前
已完结
TRP Channels and Migraine: Recent Developments and New Therapeutic Opportunities
9天前
已完结
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
26天前
已完结
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
26天前
已完结
The role of allergy in the cycle of tuberculous infections
1个月前
已完结
Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
2个月前
已完结
Bioequivalence of rimegepant, a small molecule CGRP receptor antagonist, administered as an oral tablet, a sublingual orally disintegrating tablet, and a supralingual orally disintegrating tablet: two phase 1 randomized studies in healthy adults
2个月前
已完结
Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment
2个月前
已完结
Rimegepant: Acute Treatment for Migraine Headaches
2个月前
已完结
CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention
2个月前
已完结
皖公网安备34019202002308
